Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development segments. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and locomotion and pain management products for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for dogs and cats under the Specific brand; distributes veterinary pharmaceuticals and equipment; and offers financial services. The company markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+44-1606-814730
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales£444.40 million
Profitability
Miscellaneous
Employees1,437
Next Earnings DateN/A
OptionableNot Optionable
Dechra Pharmaceuticals (LON:DPH) Frequently Asked Questions
What is Dechra Pharmaceuticals' stock symbol?
Dechra Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "DPH."
How often does Dechra Pharmaceuticals pay dividends? What is the dividend yield for Dechra Pharmaceuticals?
Dechra Pharmaceuticals declared a dividend on Monday, February 25th. Stockholders of record on Thursday, March 7th will be given a dividend of GBX 9.50 per share on Monday, April 8th. This represents a dividend yield of 0.38%. The ex-dividend date of this dividend is Thursday, March 7th. The official announcement can be accessed at this link. View Dechra Pharmaceuticals' Dividend History.
What price target have analysts set for DPH?
5 brokerages have issued 12-month target prices for Dechra Pharmaceuticals' shares. Their forecasts range from GBX 2,100 to GBX 3,000. On average, they anticipate Dechra Pharmaceuticals' stock price to reach GBX 2,711 in the next twelve months. This suggests a possible upside of 4.4% from the stock's current price. View Analyst Price Targets for Dechra Pharmaceuticals.
What is the consensus analysts' recommendation for Dechra Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dechra Pharmaceuticals.
Has Dechra Pharmaceuticals been receiving favorable news coverage?
News headlines about DPH stock have been trending neutral recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dechra Pharmaceuticals earned a news impact score of 0.4 on InfoTrie's scale. They also gave news stories about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
Who are some of Dechra Pharmaceuticals' key competitors?
Some companies that are related to Dechra Pharmaceuticals include Hutchison China MediTech (HCM), Mayne Pharma Group (MYX), Vectura Group (VEC), Medical Developments International (MVP), Eco Animal Health Group (EAH), BEXIMCO PHARMAC/S GDR REGS (BXP), Opthea (OPT), Trilogy International Partners (TRL), Pharmaxis (PXS), Allergy Therapeutics (AGY), Vita Life Sciences (VLS), Futura Medical (FUM), Avivagen (VIV), Cathay International (CTI) and Recce Pharmaceuticals (RCE).
What other stocks do shareholders of Dechra Pharmaceuticals own?
Who are Dechra Pharmaceuticals' key executives?
Dechra Pharmaceuticals' management team includes the folowing people:
- Mr. Ian D. Page, CEO, MD & Exec. Director (Age 58)
- Mr. Richard John Cotton, CFO & Director (Age 58)
- Dr. Anthony Gerard Griffin, MD of Dechra Veterinary Products for Europe & Exec. Director (Age 56)
- Ms. Katy Clough, Group HR Director
- Mr. Mike Eldred, Pres of North America (Age 49)
How do I buy shares of Dechra Pharmaceuticals?
Shares of DPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Dechra Pharmaceuticals' stock price today?
One share of DPH stock can currently be purchased for approximately GBX 2,596.
How big of a company is Dechra Pharmaceuticals?
Dechra Pharmaceuticals has a market capitalization of £2.66 billion and generates £444.40 million in revenue each year. Dechra Pharmaceuticals employs 1,437 workers across the globe.
What is Dechra Pharmaceuticals' official website?
How can I contact Dechra Pharmaceuticals?
Dechra Pharmaceuticals' mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The company can be reached via phone at +44-1606-814730.
MarketBeat Community Rating for Dechra Pharmaceuticals (LON DPH)
MarketBeat's community ratings are surveys of what our community members think about Dechra Pharmaceuticals and other stocks. Vote "Outperform" if you believe DPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
